Treament of rhumetic fever and fhumetic h3art disease

Reading File
Finding Sources
Finding Sources
Searching PubMed

"rheumatic fever" AND "rheumatic heart disease" treatment

Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
I now have comprehensive information from multiple authoritative textbooks. Let me compile the complete answer.

Treatment of Rheumatic Fever and Rheumatic Heart Disease


Acute Rheumatic Fever (ARF)

1. Eradication of Group A Streptococcus (Primary Step)

Immediate eradication of GAS is standard practice even before throat culture results are available.
Drug of choice:
  • Benzathine penicillin G (BPG) IM - single dose
    • 27 kg (60 lb): 1.2 million units IM
    • <27 kg: 600,000 units IM
Alternatives (oral, less effective):
  • Penicillin V 250 mg twice daily x 10 days
  • Amoxicillin 50 mg/kg once daily (max 1 g) x 10 days
  • Azithromycin 250 mg daily (for penicillin-allergic patients)
  • Erythromycin 40 mg/kg/day (max 1 g/day) divided 2-4 doses x 10 days
Goldman-Cecil Medicine, 2-Volume Set

2. Anti-inflammatory Therapy

For Arthritis and Fever

Arthritis and fever almost always respond to NSAIDs within hours - if not within 3 days, reconsider the diagnosis.
  • Aspirin - first-line; 80-100 mg/kg/day in children (4-8 g/day in adults), in divided doses
  • Naproxen 10-20 mg/kg/day divided twice daily - used with success in small studies as an alternative
  • NSAIDs should continue for 1-2 weeks until ALL symptoms have resolved (not just joint symptoms)
Goldman-Cecil Medicine; Firestein & Kelley's Textbook of Rheumatology

For Carditis (Severe)

  • Prednisone 1-2 mg/kg/day (max 80 mg/day, once daily or divided) is the glucocorticoid of choice
  • After 2-3 weeks, taper by 20-25% weekly
  • The 2020 Australian guidelines list glucocorticoids as optional for very severe carditis; high-quality evidence is still limited
  • IV methylprednisolone is recommended by WHO and NZ/Australian guidelines in life-threatening situations
  • After stopping glucocorticoids, resume NSAIDs to prevent rebound fever and joint symptoms
  • IVIG was not shown to alter the natural history of ARF and is NOT recommended
Firestein & Kelley's Textbook of Rheumatology, 2-Volume Set

For Heart Failure (due to carditis)

  • Diuretics
  • Angiotensin receptor blockers (ARBs)
  • Fluid restriction and bed rest
  • Beta-blockers are not currently recommended for HF due to acute carditis
  • Valve surgery is rarely needed in acute ARF, but can be helpful in cases of acute valve leaflet rupture

For Sydenham's Chorea

  • Usually resolves within weeks to months without treatment
  • Valproic acid or carbamazepine can be used for severe or persistent cases
  • Haloperidol (low dose) has also been used in refractory chorea

3. Bed Rest

  • Strict bed rest is no longer universally recommended
  • Normalization of ESR and CRP is used as a practical guide for return to exercise

Secondary Prophylaxis (Preventing Recurrence)

This is the most important long-term intervention. Since streptococcal pharyngitis is often asymptomatic, prevention requires continuous antimicrobial prophylaxis rather than treating only symptomatic episodes.
BPG reduces new streptococcal pharyngitis by 71-91% and new ARF episodes by 87-96%.

Drug of Choice:

RegimenDoseRouteFrequency
Benzathine penicillin G (preferred)1.2 million units (>27 kg); 600,000 units (<27 kg)IMEvery 4 weeks (every 3 weeks for high-risk patients)
Penicillin V250 mgOralTwice daily
Erythromycin (penicillin-allergic)400 mg (adults); 40 mg/kg/day (children, max 1 g/day)OralTwice daily
IM BPG is more effective than oral penicillin for preventing recurrences.

Duration of Secondary Prophylaxis:

CategoryDuration
ARF without carditis5 years OR until age 21 (whichever is longer)
ARF with carditis, no residual valve disease10 years OR until age 21 (whichever is longer)
ARF with carditis + persistent valve disease10 years OR until age 40 (whichever is longer), sometimes lifelong
Severe valvular disease / after valve surgeryLifelong
Firestein & Kelley's Textbook of Rheumatology; Goldman-Cecil Medicine

Rheumatic Heart Disease (RHD)

RHD is almost exclusively a valvular disease. The mitral valve is affected in nearly 100% of cases; the aortic valve in 20-30%. Mitral regurgitation is most common; mitral stenosis is the most common cause of acquired mitral stenosis worldwide.

Medical Management:

  • Continue secondary prophylaxis (BPG as above) - this is the cornerstone
  • Echocardiography for diagnosis, follow-up, and surveillance
  • Atrial fibrillation (a frequent complication) - rate control and anticoagulation (warfarin preferred over NOACs in RHD-associated AF)
  • Heart failure - standard HF therapy (diuretics, ACE inhibitors/ARBs, beta-blockers)
  • Infective endocarditis prophylaxis - per current guidelines for high-risk valve lesions

Interventional/Surgical Management:

Indicated for severe or symptomatic valvular disease:
  • Percutaneous mitral balloon valvotomy (PMBV) - procedure of choice for suitable mitral stenosis (pliable, non-calcified valve, no significant MR)
  • Mitral valve repair or replacement - for severe mitral regurgitation or calcified/unsuitable stenotic valves
  • Aortic valve repair or replacement - for significant aortic regurgitation or stenosis
  • Catheter-based interventions are the first consideration per current valvular disease guidelines
Goldman-Cecil Medicine; Firestein & Kelley's Textbook of Rheumatology; Sabiston Textbook of Surgery

Summary Table: ARF Treatment at a Glance

ProblemTreatment
GAS eradicationBenzathine penicillin G IM (single dose)
Arthritis / FeverAspirin 80-100 mg/kg/day or Naproxen
Severe carditisPrednisone 1-2 mg/kg/day; IV methylprednisolone if life-threatening
Heart failureDiuretics, ARBs, fluid restriction
ChoreaUsually self-limiting; valproate/haloperidol if severe
Secondary prophylaxisMonthly BPG IM (every 3 weeks for high-risk); duration per category
Valvular diseasePMBV, valve repair/replacement per severity

Recent evidence note: A 2024 Cochrane systematic review (PMID 39312290) on long-term antibiotic prophylaxis for preventing RHD progression confirms BPG remains the cornerstone of secondary prevention, consistent with current guidelines. A separate 2024 meta-analysis (PMID 39542478) found adherence to secondary prophylaxis remains a major challenge globally, highlighting the need for patient education and structured follow-up programs.
This is a shared conversation. Sign in to Orris to start your own chat.